A major challenge for translating cell-based therapies is understanding the dynamics of cells and cell populations in complex in vivo environments. Intravital microscopy has shown great promise for directly visualizing cell behavior in vivo. However, current methods are limited to relatively short imaging times (hours), by ways to track cell and cell population dynamics over extended time-lapse periods (days to weeks to months), and by relatively few imaging contrast mechanisms that persist over extended investigations. We present technology to visualize and quantify complex, multifaceted dynamic changes in natural deformable skin over long time periods using novel multimodal imaging and a non-rigid image registration method. These are demonstrated in green fluorescent protein (GFP) bone marrow (BM) transplanted mice to study dynamic skin regeneration. This technology provides a novel perspective for studying dynamic biological processes and will enable future studies of stem, immune, and tumor cell biology in vivo.
Mullerian Inhibiting Substance (MIS) has been shown to inhibit ovarian cancer cells both in-vitro and in-vivo. Furthermore, recent evidence suggests that MIS may effectively target a putative ovarian cancer progenitor cell population enriched by a panel of CD44+, CD24+, Ep-CAM+, and E-cadherin-cell surface markers. In order to accommodate clinical testing of MIS in ovarian cancer patients, the production of recombinant human MIS must be optimized to increase yield and purity. Here we show that, compared to wild type, the substitution of the MIS leader sequence to that of human serum albumin, combined with a modification of the endogenous cleavage site from RAQR/S to a furin/kex2 RARR/S consensus site results in high expression, increased C-terminus cleavage and a reduction in unwanted cryptic internal cleavage products when produced in CHO cells. Purified MIS containing these alterations retains its capacity to induce regression of the Mullerian duct in fetal rat embryonic urogenital ridge assays.